The U.S. pediatric priority review voucher (PRV) program hit a new high, with three additional vouchers issued since August for drugs targeting rare pediatric diseases. The tally places pediatric PRVs just one away from the record 11 granted in 2023. The recent approvals also coincided with a drop in PRV fees, a dynamic that can influence sponsor behavior and transaction values in the voucher market. Lower costs may broaden access to voucher monetization while still creating incentives to pursue pediatric indications. For biotech companies preparing submissions, the PRV pipeline continues to function as a financing lever and as an acceleration tool when paired with regulatory-ready pediatric data packages.